Nerinetide is under clinical development by NoNO and currently in Phase II for Subarachnoid Hemorrhage. According to GlobalData, Phase II drugs for Subarachnoid Hemorrhage does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Nerinetide LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nerinetide overview
Nerinetide is under development for the treatment of acute ischemic stroke including strokes with endovascular intervention, procedurally-induced strokes, aneurysmal subarachnoid hemorrhage, traumatic brain injury and ischemic cerebral stroke. The therapeutic candidate is administered through intravenous infusion. NA-1 (also known as Tat-NR2B9c) acts by targeting PSD-95 a postsynaptic scaffolding protein.
It was also under development for the treatment of stroke, retinal ischemia, pain, epilepsy, Alzheimer’s disease and anxiety.
NoNO overview
NoNO is a clinical-stage biotherapeutics company that provides research, development and commercialization of medicines for the treatment of neurological disorders. The company’s pipeline products include Nerinetide and PSD-95. Nerinetide is a 20 amino acid peptide designed for intravenous infusion to cure acute ischemic stroke. NoNO-SC is an injectable PSD-95 inhibitor that may be used to treat subacute and chronic neurological diseases, such as stroke recovery, vascular dementia, Alzheimer’s, and retinal ischemia. The company holds expertise in the development of safe and effective treatment for acute neurological disorders, especially acute ischemic strokes. NoNO is headquartered in Toronto, Ontario, Canada.
For a complete picture of Nerinetide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
